# Supplementary Materials

Table S1. Category and dosage of PD-1 inhibitors used in the two groups

Category	Dose (mg)	N = 442 No. (%)
Nivolumab (Bristol-Myers Squibb)	100	29 (6.6)
Pembrolizumab (Carlow, Merck Sharp & Dohme Corp)	200	34 (7.7)
Toripalimab (Suzhou, hezhong pharmaceutical Co.Ltd)	240	277 (62.7)
Sintilimab (Suzhou, xinda pharmaceutical Co.Ltd))	200	94 (21.3)
Camrelizumab (Suzhou, shengdiya pharmaceutical Co.Ltd)	200	28 (6.3)

Figure S1. Schematic of the method used to determine the optimal cutoff points of PLR, NLR, LCR, LMR, SII, CAR, and PNI using X-tile software for survival prediction.

Figure S2. Time-dependent receiver operating characteristic (ROC) curves for survival prediction of inflammation-based scores at (A) 6 months, (B) 12 months, (C) 18 months, and (D) 24 months in HCC patients after anti-PD-1 therapy.